Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.
The vaccine, known as DS-5670, was picked for the second round of AMED's program dedicated to COVID-19 research. Daiichi Sankyo is aiming to begin clinical studies of the vaccine around March 2021 in collaboration with the University of Tokyo.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.